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Abstract 
A PRELIMINARY STUDY EVALUATING POTENTIAL PROBIOTIC USE IN 
ENDODONTICS 
Khaled Seifelnasr, BDS, DDS 
Introduction: 
The main goal of endodontics is the prevention of apical periodontitis.  This condition is 
the result of persistent pathogenic microorganisms such as Enterococcus faecalis (E. f) and 
Candida albicans (C. a) remaining in the root canal systems of teeth, and the ability of those 
organisms to directly cause acute and chronic inflammation in the periapical tissues.  The 
concept of the use of probiotics has not yet been evaluated in addressing endodontic disease, but 
probiotics have proven successful in treating periodontal disease.  Taking these findings into 
account, this preliminary work was performed to evaluate the possible effectiveness of a 
probiotic cocktail in preventing the growth of two potential endodontic patogens, Enterococcus 
faecalis and Candida albicans. 
Materials and methods: 
Five groups (I, II, III, IV and V) of commercial probiotics were selected and evaluated 
based upon numbers and concentration of organisms.  Pathogenic test organisms were C.
albicans (WVU Isolate Ca1028) and E. faecalis (WVU Isolate Ef01).
Phase 1 of the study was conducted by a disc diffusion assay test to evaluate zones of 
inhibition (ZOI) in millimeters (mm) of the selected probiotics against the E. f and C.a.
Microorganisms from probiotic samples were extracted via manufacturer’s recommendations 
and mixed by weight.  Thirty (30) microliters were then placed on sterile discs.  Pathogenic 
organisms were set to a 1 McFarland standard challenge.  A five probiotic disc template on blood 
agar plates were inoculated with a lawn of either E. F or C. a and incubated at 37° C for 48 hours 
and 1 week.  Two, five sterile disc templates with a lawn of either pathogenic organism were run 
parallel as a control.  
Phase 2 was conducted by mixing 9 ml of 30% poloxamer 407 and MRS broth in a test 
tube with 500 ml of either E. f or C. a set at a 1 McFarland standard, together with 500ml of 
either Group I or Group IV probiotic mixtures, set at a 2 McFarland standard.  Samples were 
incubated at 37°C for 48 hours, followed by serial dilutions of 10-2, 10-4, and 10-6 for evaluation 
of CFU/ml counts.  Controls were E. f or C. a 30% poloxamer with MRS broth and no 
probiotics.  
 Results: 
Phase 1: Based on a One-Way ANOVA analysis, Groups I, IV and V showed the most 
statistically significant results (P< 0.05) with a Mean of 7.4mm,10.05mm,11.2mm for C. a and a 
Mean of  6.7 mm,11.1 mm, and 12.5 mm for E. f respectively at 1 week, compared with no ZOI 
for the control. L. acidophilus, L. casei , L. rhamnosus  and B. longum were all common strains 
in the probiotic cocktails selected. 
Phase 2: Initial results showed a decrease to a 2 log difference and a 1 log difference for 
groups I and IV respectively regarding CFU/ml counts for C. a and for E. f.   Probiotic Groups I
and IV showed complete elimination of E. f and only probiotic colonies were present on 
observation. 
Conclusion: 
Recognizing that probiotics may act differently based on their composition and 
concentration, this study suggests that organisms such as L. acidophillus, L. rhamnosus, L.casei
and B. Longum are effective for preventing the growth of E. faecalis and C. albicans in vitro 
against both their planktonic and biofilm morphological stages.   Further evaluations for possible 
use in treating endodontic infection is suggested and warranted.  Additionally, Phase 2 results of 
the study suggest that poloxamer 407 could be utilized as an ideal probiotic delivery vehicle 
when mixed with appropriate probiotics and utilized as an endodontic intra-canal medicament for 
treating teeth that have presented with non-vital pulps. 
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CHAPTER 1 
Introduction 
Apical periodontitis is defined as inflammation and destruction of periradicular tissues 
caused by the presence of etiological agents of endodontic origin. (1) It has long been known that 
these agents have been recognized as being either microorganisms or their metabolic products.
(1,2,3,6,7,8) It has been shown experimentally that no apical periodontitis develops in germ free 
rats, even when their mechanically exposed molar pulps are left in direct contact with the oral 
cavity, as opposed to control specimens with a conventional oral microflora, and in which 
massive periapical radiolucencies were observed. (2) 
According to multiple studies, (1, 3, 4, 5, 6, 7) bacteria that normally inhabit the oral cavity 
have the ability to invade root canal systems during and after pulp necrosis. Microorganisms 
present in infected root canals are known to include a restricted group of species when compared 
to the rest of the normal flora found in the oral cavity. (1, 3) Most of the species that have been 
found in infected root canals have also been identified in periodontal pockets. (3) Conditions 
exist in root canal systems that permit growth of anaerobic bacteria because they are capable of 
fermenting amino acids and peptides for metabolic needs. Bacteria that obtain energy mainly 
through the fermentation of carbohydrates have more restricted growth potential due to the lack 
of sufficient, appropriate and available nutrients in that specific environment.  During the course 
of infection, interrelationships develop between microbial species, and microbial population 
shifts are produced as a result of these interactions. (1, 3, 4)  These microbial interactions play a 
significant role in the ecological regulation and eventual development of an endodontic habitat
adapted polymicrobial flora. (1)
It has long been held that there are three basic principles that must be adhered to in 
clinical endodontics in order to achieve success in endodontic therapy. Also known as the 
“endodontic triad”, these three principles are (1) thorough debridement of the root canal system,
(2) sterilization of the root canal system, and finally (3) complete obturation of the root canal 
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system. A key question in endodontics which continues to remain unanswered is, “Can 
pathogenic microorganisms actually be eliminated from an infected root canal”?
It has been proposed that it is impossible to obtain complete sterility within any given 
root canal system. Microscopic examination of serial sections of roots of many teeth have 
demonstrated the prevalence of multiple accessory and lateral canals.(9)  It is currently believed 
that these branches and ramifications can never be either completely debrided of tissue or 
properly rendered sterile.  It is recognized and acknowledged that all that can be achieved is a 
reduction in the number of microorganisms in the main canal, or in other words, a reduction in 
the so called “bioload”. Any perceived clinical success obtained from treatment of teeth with 
known positive root canal cultures can probably be ascribed to a reduction in the number of 
microorganisms, removal of most inflamed or necrotic tissue, and a favorable systemic 
background. (1, 9) Findings from multiple studies lead to speculation that there is a missing link 
or some unknown etiological factor in endodontic theory and practice. 
This “missing link” could be an ongoing misunderstanding and even possibly incorrect
concept of endodontic infection, with that thinking being restricted to the belief that all 
microorganisms must be removed from the root canal system, regardless of their pathogenicity or 
other characteristics.  Rather, and in light of current and emerging findings in microbiology, it 
now seems reasonable that a better approach to addressing and dealing with microbial infection 
should be to maintain a state of equilibrium within the “Human Microbiome”.  The “Human 
Microbiome” is defined as “the recognized, normal microbial component of all humans and 
animals which is needed for health.”(27,28) Multiple studies have demonstrated that the human 
microbiome is a necessary component for the health of the host, and that alterations in its 
ecological equilibrium can lead to disease; therefore, logic suggests that it is necessary to 
maintain a continuous state of equilibrium between these diverse microbial communities in order 
to maintain health.(27,28)
Accepting that the dentition is a part of the Oral Human Microbiome, it is proposed that
there should be, of necessity, healthy organisms (probiotics) associated with the teeth in order to 
establish endodontic health, since complete sterility is impossible anywhere within the oral 
cavity.  Therefore, to maintain or restore the equilibrium of the endodontic infrastructure, the
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host could be provided with microbiota which would then produce beneficial effects, shifting any 
deficiencies to a more favorable ecological system. 
“Probiotics”, as defined by the World Health Organization, are, live microorganisms 
which, when administered in adequate amounts, confer a health benefit on the host”.  Probiotics 
have been successfully used to control gastrointestinal diseases and appear to act through 
colonization resistance and/or immune modulation. (27, 28)
Recently, probiotics have been introduced to dentistry for the treatment or prevention of 
disease. Experimental studies and clinical trials have demonstrated that certain gastrointestinal 
bacteria may control the growth of some oral microorganisms, including those cariogenic species 
associated with dental decay.  Probiotics might potentially provide a means of preventing dental 
caries.(10,11,14,17,19) The oral administration of  probiotics has also been explored in the control of 
periodontal disease by reducing plaque levels and gingival inflammation.(11, 24)
The purpose of this study is to evaluate the potential use of probiotic therapy as an 
adjunct in endodontic therapy along with its effect on the reduction or elimination of apical 
periodontitis.
  
Figure 1: Healing RCT with no canal 
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Statement of the Problem 
Does the use of probiotics have the potential to outcompete or eliminate pathogenic 
microorganisms in endodontic therapy? 
 
Significance of the Problem 
There is a need for an innovative or novel approach to the current treatment modalities 
which can possibly result in a higher, long term success in endodontic therapy.  Despite the 
universal and widely spread advancement of technology throughout all facets of dentistry, the 
same basic approach, in conjunction with the same materials, has been employed over the past 
several decades in providing endodontic treatment.  The concept of the “Human Microbiome” 
has been neglected in the development of new and better strategies used in endodontic therapy, 
even though it is now known to be an integral and undeniable part of human health.  The novel 
concept in endodontics that the intentional establishment of a microbial equilibrium inside the 
root canal system by utilizing probiotics, a procedure which might result in improved overall 
success rates in the reduction of apical periodontitis, needs to be carefully examined and 
explored.  As previously mentioned, the use of probiotics has gained universal acceptance by the 
gastroenterology community and some probiotics have been shown to be successful in treating 
certain gastrointestinal diseases. The concept of using probiotics has recently been utilized for 
the prevention of both dental caries and periodontal disease.  Periodontal disease is known to 
have a number of pathogenic microorganisms in common with those found in endodontic 
infections, and therefore utilizing probiotics within the root canal system may also be found to be 
beneficial in endodontics. 
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 Null-Hypothesis 
There is no significant difference between probiotic therapy and no therapy in eliminating 
or decreasing the amount of Enterococci faecalis and Candida albicans in planktonic and 
biofilm microbial stages when tested in an in vitro model.
Assumptions 
1. The Human Microbiome theory is gaining acceptance in medicine but has not yet been 
evaluated in endodontics. 
2. Maintaining or restoring equilibrium with probiotics may show promising results in 
endodontic therapy. 
3. Although sterility of the endodontic system is deemed necessary for endodontic success, 
achieving complete sterility is currently impossible under normal conditions. 
4. Probiotics used against test organisms evaluated in vitro in both planktonic and biofilm 
stages in terms of measurement of zones of inhibition (ZOE) is an acceptable method of 
evaluation of the efficacy of the probiotics against pathogenic organisms. 
5. Synergistically acting probiotics tested against pathogenic organisms may give a broader 
understanding of which particular species to select when conducting future studies. 
6. Gram staining is an effective method to evaluate which organisms are present in blood 
agar/MRS or Muller Hinton plates. 
7. Live/dead staining is an appropriate method of identifying probiotic activity. 
8. Poloxamer 147 mixed with MRS broth and probiotics is a novel delivery vehicle for the 
introduction of probiotics into the root canal system as an intra-canal medicament.  
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Limitations 
1. Due to financial limitations, commercial probiotics were utilized, and probiotic 
organisms were extracted either in groups or individually, according to manufacturer’s 
instruction. 
2. Due to time limitations, experiments were not performed in teeth. 
3. As in any experimentation, human error may exist. 
4. There is no known standardized method to identify different strains of microorganisms 
mixed together in a single group. 
5. There have been no studies involving the use of probiotics in endodontics.  The effective 
CFU count needed to eliminate or out compete the pathogenic organisms was unknown. 
Delimitations 
1. Manufacturer was contacted to determine the method for extraction of probiotic species 
from commercial samples. 
2. 50 Muller Hinton plates were utilized for initial evaluation. 
3. 100 blood agar plates were utilized for evaluation of probiotic mixture against pathogenic 
organisms. 
4. Probiotics and pathogenic organisms E. feacalis and C. albicans were tested in both 
planktonic and biofilm stages.  
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Chapter II 
Review of Literature 
The microbial component of humans and animals has been termed the indigenous 
microbiota.  Experimental evidence shows that the microbiome is necessary for the health of the 
host, and that alterations in the ecological equilibrium of these microbes can lead to disease. (26)
It is therefore logical to expect that the introduction of microbes that are also members of the 
microbiome into an area of interest could help restore an ecological balance. (26)
A proposed solution to maintaining or restoring equilibrium would be to provide the host 
with microbiota which would produce perceived beneficial effects, shifting any deficiencies to a 
more favorable ecological system. The term “probiotics” is defined by the World Health 
Organization as live microorganisms which, when administered in adequate amounts, confer a 
health benefit on the host.  The word “probiotics” was derived from the Greek, meaning “for 
life”. The concept of probiotics is not new, but rather dates back to 1908, when Nobel Prize 
winner, Ukrainian bacteriologist Ilya Metchnikoff, suggested that the long life of Bulgarian 
peasants resulted from their consumption of fermented milk products which contained 
lactobacillus. (11,12,13,14,15,16,17,18,19,20,21,22,23,24) 
Another solution to maintaining and/or restoring microbial equilibrium would be to 
administer substrates that improve the growth or metabolic activities of specific indigenous 
organisms, or so called, “prebiotics”. The term prebiotic was introduced by Gibson and 
Roberfroid who exchanged “pro” for “pre”, meaning “before”.  They defined prebiotics as a 
“non-digestible food ingredient that beneficially affects the host by selectively stimulating the 
growth and/or activity of one or a limited number of bacteria in the colon”. (18)  Experimental 
models, along with several human studies, have shown that food ingredients, products, and 
supplements demonstrating a prebiotic effect, have been shown to modulate certain 
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immunological biomarkers and affect activities of the immune system by inducing change in the 
gut microbiota. (29)
The term “synbiotic” is used when a product contains both probiotics and prebiotics. 
According to this approach, a food or food supplement will include not only live cells of the 
beneficial bacteria, but also their selective substrates, with the idea being that beneficial bacterial 
cells can grow quickly and competitively because of the presence of the selective substrate which 
allows it to predominate in the proposed environment.(18) 
The introduction of these probiotics, prebiotics and synbiotics are coined as 
“Bacteriotherapy”.  Bacteriotherapy has been investigated in multiple studies to control 
infectious diseases, especially gastrointestinal disease, with the objective being the restoration 
and balance of the human microbiome. (14)   
The suggested mechanisms of probiotic action on oral health are drawn from 
gastrointestinal studies.  These several mechanisms include but are not limited to, immune 
modulation, down regulation of inflammatory responses, production of antimicrobial substances 
such as peroxides, organic acids and bacteriocins, mucin production, inhibition of epithelial 
invasion by inhibition of pathogens mucosal adherence, stimulation of IgA, and competition with 
other flora, including potential pathogens. (12, 13, 14, 17, 18, 19) 
Ideal features of a good probiotic would be: 
(a) It should be a strain which is capable of exerting beneficial effect to the host  
(b) It should be non-pathogenic and non-toxic  
(c) It should be present as viable cells, preferably in large numbers  
(d) It should be capable of surviving in the host environment  
(e) It should also be able to maintain genetic stability in oral micro flora  
(f) It should be stable and capable of remaining viable for periods under storage and field 
conditions. (12, 13, 14, 17, 18, 19) 
The most common probiotic bacteria belong to the Lactobacilli and Bifidobacteria
genera, but certain strains of Streptococci have also been investigated. (22) The reasoning behind 
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why Lactobacillus species were chosen for this experiment is because they aide in producing 
those enzymes which digest and metabolize proteins and carbohydrates.  They also aid in the 
synthesis of vitamins B and K, facilitating the breakdown of bile salts.  Additionally, they have 
the ability to help enhance innate and acquired immunity, along with inhibiting pro-
inflammatory mediators.   Lactobacilli are considered to be a genus of gram positive facultative 
anaerobic microorganisms, with more than 100 species identified.   Most notable are the strains 
L. acidophilus, L. salivarius, L. rhamnous, L. brevis, and L. casei which are utilized as 
probiotics. (14)
  Another organism as mentioned above is the Bifidobacterium species which are strictly 
gram positive anaerobes and which are the dominant organism found in the large intestine.  Over 
30 species of Bifidobacterium have been identified.  Their characteristics include metabolism of 
lactose, generation of lactic ions from lactic acid, vitamin synthesis, fermentation of indigestible 
carbohydrates, and production of beneficial short chain fatty acids. (10, 12, 14, 17, 18, 19) Other species 
such as Streptococcus thermophillus are the organisms used as the chief cultures in yogurt 
production, owing to their distinguishing benefits of metabolism of lactose and improving 
lactose intolerance, while also possessing antimicrobial activity. Saccharomyces boulardii is a 
non-colonizing lactic acid producing yeast.  Their most preeminent feature is that they secrete 
proteases and other substances that break down bacterial enterotoxins.   They also help in the 
enhancement of immune function and have been shown to be beneficial in helping with C.
difficile management. (30)
Recently, probiotics have been introduced in dentistry as an adjunct for the treatment or 
prevention of oral diseases.  Currently, probiotic therapy has been investigated in experimental 
studies and clinical trials in an attempt to establish equilibrium in the oral component of the 
human microbiome.  This philosophy would eliminate microorganisms associated with disease 
by allowing others associated with health to evolve and predominate.   
Experimental studies and clinical trials are beginning to show advancement in multiple fields 
of dentistry such as:  
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 Caries Control:  
In saliva, caries associated microbes such as Streptococcus mutans have been 
shown to be reduced in number after the consumption of products containing the 
probiotics Lactobacillus and Bifidobacteria. (11, 21)
 Periodontal disease:
Initial studies suggested that the use of probiotics could enhance oral health by 
decreasing periodontal inflammation. (31)  Subsequent studies evaluating patients who 
presented with various forms of periodontal disease such as gingivitis, pregnancy 
gingivitis and periodontitis, showed significant recovery after treatment with a culture of 
the L. acidophilus strain in most patients. (32) Another study evaluated probiotic strains 
including L. reuteri , L. brevis and L. casei which revealed an improvement in gingival 
health, as measured by decreased gum bleeding. (33) Further studies evaluated L. reuteri,
L. brevis and L. salivarius  probiotic strains against inflammatory markers where L. 
reuteri showed decreased levels of pro-inflammatory cytokines in gingival crevicular 
fluid(33) and the use of L. brevis and L. salivarius decreased matrix metalloproteinase 
activity along with other inflammatory markers in saliva.(34)
 Oral Candidiasis: 
A preliminary study investigated the probiotic bacteria L. acidophilus and L. 
fermentum in oral cavities, which resulted in a rapid decline in C. albicans after the 
intake of the probiotics.  Further consumption led to an almost undetectable number of 
fungi in the oral cavity. (35) Another study evaluated L. rhamnosus and 
Propionibacterium freudenreichii ssp. shermanii for the effect on oral candida infection 
in humans.  After 16 weeks of therapy, the number of high oral yeast counts decreased, 
but no changes were observed in mucosal lesions. (35).
 Halitosis: 
A few clinical studies have found probiotic strains effective for the treatment of 
oral or gut associated halitosis. The studied strains included Lactobacillus, E. coli Nisle,
S. salivarius and  Weissella confusa isolates.(36)   In endodontics, it has long been held that 
there are three basic principles that must be adhered to in order to achieve success. This is 
known as the endodontic triad where, if followed, the end result of endodontic treatment 
should be both clinical and radiographic success. These three “principles” are (1)
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thorough debridement of the root canal system, (2) sterilization of the root canal system,
and (3) complete obturation of the root canal system.  As previously stated, the question 
which still remains today is whether or not microorganisms can be eliminated from an 
infected root canal system.
It has been proposed that attaining complete sterility in any part of the human oral cavity 
is impossible.  Histological examination of serial sections of the roots of many teeth have 
revealed the prevalence of multiple accessory and lateral canals.(9) It is inconceivable that these 
branches can be either debrided properly or made completely free of bacteria.  All that can be 
reasonably expected and achieved in conventional root canal therapy is a reduction in the number 
of microorganisms within the main canal.  Any success obtained from treatment of teeth with 
positive root canal cultures can be ascribed to a reduction in the number of microorganisms, 
removal of most inflamed or necrotic tissue, and a favorable systemic background. (1, 9) Multiple 
pathogenic organisms have been attributed to endodontic failure, but the two organisms in 
particular most commonly associated with treatment failure are E. faecalis and C. albicans.(8)
E. faecalis is resistant to most of the intra-canal medicaments, particularly calcium 
hydroxide dressings.  This is due to its ability to regulate internal pH with an efficient proton 
pump, as well as its ability to survive prolonged starvation.  Although endodontic infections are 
considered to be polymicrobial in nature, it has been shown that E. faecalis is the pathogen of 
significance in most failing endodontic treatment cases. (37, 38)
Microbiological and correlative electron microscopic studies have shown the presence of 
yeasts in canals of teeth with apical periodontitis.(1) Candida albicans is the most frequently 
isolated fungus from root filled teeth with apical periodontitis.(3)
The literature shows that there is a need for an innovative method of handling endodontic 
infections other than the currently used methods.  A promising approach would be to manage 
endodontic treatment as part of the human microbiome and utilize probiotics in the same manner 
that they are used for other oral conditions to reestablish equilibrium of healthy flora. 
Probiotics testing should be done against both planktonic and biofilm stages, the rationale 
being that although planktonic organisms represent free floating and homogeneous microbial 
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cells, there has been a paradigm shift showing a link between surface attached, heterogeneous 
microbial cells (biofilms) and microbial pathogenesis, which then leads to human infections.(39)
Biofilms are defined as highly structured communities of microorganisms that are either surface 
associated or attached to one another and which are enclosed within a self-produced, protective 
extracellular matrix (ECM).   Biofilm formation provides protection from the environment, 
resistance of physical and chemical stress, metabolic cooperation, and a community based 
regulation of gene expression. (39, 40, 41) These features allow organisms (bacteria and fungi) in 
biofilms to assume a stronger pathogenic potential than those solely in a planktonic state. (40)
There is also evidence showing a major role of fungi in biofilm formation and disease. (41)
Chapter III 
Materials and Methods 
 Probiotic Strain Selection: 
Due to financial limitations, individual probiotic strains were not able to be purchased 
from ATCC (American Type Culture Collection).  Alternatively, commercial probiotic cocktails 
were purchased for utilization in this study, decreasing financial burden.  After extensive 
research was conducted about effective probiotic strains used to establish equilibrium of the gut 
flora, five probiotic cocktails were purchased from Klaire Labs®.  The probiotic cocktails were 
delivered in wrapped ice packaging in order to preserve viability of the organisms. Upon
arrival, the probiotics were stored in a refrigerator at 30º F. Each group of probiotic blend was 
designated a specific color to easily identify the group for the study.  The five groups (G I, GII,
GIII, GIV and GV) of commercial probiotics were selected and evaluated based upon numbers 
and concentration of organisms. 
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The five commercial groups of probiotics were as follows: 
I. Group 1: Designated Color =YELLOW  
 Vital-Immune Biotic® Caps  
Amount Per Capsule % Daily Value 
Probiotic Blend (5+ billion CFUs) in 
a baseof inulin (derived from 
chicory root) 
460 mg * 
Lactobacillus rhamnosus 2.0+ billion 
CFUs 
* 
Lactobacillus casei 1.5+ billion 
CFUs 
* 
Lactobacillus acidophilus 1.0+ billion 
CFUs 
* 
Bifidobacterium longum 0.5+ billion 
CFUs 
* 
 
 
 Figure 2: Probiotic Group 1 (Yellow)
II. Group 2: Designated Color =RED                                    
ABx Support™  
Amount Per Capsule % Daily 
Value 
Probiotic Blend (10+ 
billion CFUs) in abase of 
inulin (derived from 
chicoryroot) 
430 mg * 
Saccharomyces boulardii 5.0+ 
billion 
CFUs 
* 
Lactobacillus rhamnosus 2.5+ 
billion 
CFUs 
* 
Bifidobacterium bifidum 1.25+ 
billion 
CFUs 
* 
Bifidobacterium breve 1.25+ 
billion 
CFUs 
* 
 
 
 
Figure 3: Probiotic Group 2 (Red)
14 
 
III. Group 3: Designated Color = PURPLE
Sacchromyces Boulardii  
Amount Per Capsule % Daily Value 
 
 
Probiotic Blend in a base of cellulose 320 mg * 
 
Saccharomyces boulardii 3+Billion CFUs* 
Figure 4: Probiotic Group 3 (Purple)
IV. Group 4: Designated Color= Blue
                               Ther-Biotic® Complete Powder
Serving Size 1/4 Teaspoon 
Amount Per 1/4 Teaspoon % Daily 
Value 
Probiotic Blend (100+ billion CFUs) in 
a base of inulin (derived from chicory 
root) and InTactic® proprietary 
polysaccharide complex 
1,000 mg * 
Lactobacillus rhamnosus 24.0+ 
billion CFUs 
* 
Bifidobacterium bifidum 20.0+ 
billion CFUs 
* 
Lactobacillus acidophilus 12.0+ 
billion CFUs 
* 
Lactobacillus casei 10+ billion 
CFUs 
* 
Lactobacillus plantarum 8.0+ billion 
CFUs 
* 
Lactobacillus salivarius 8.0+ billion 
CFUs 
* 
Bifidobacterium longum 4.0+ billion 
CFUs 
* 
Streptococcus thermophilus 4.0+ billion 
CFUs 
* 
Lactobacillus bulgaricus 4.0+ billion 
CFUs 
* 
Lactobacillus paracasei 2.0+ billion 
CFUs 
* 
Bifidobacterium lactis 2.0+ billion 
CFUs 
* 
Bifidobacterium breve 2.0+ billion 
CFUs 
* 
 
 
Figure 5: Probiotic Group 4 (Blue)
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V. Group 5: Designated Color = GREEN  
                              Vital-10® Powder
Amount Per 1/4 Teaspoon % Daily Value 
 
 
Probiotic Blend (10+ billion CFUs) in 
a base of inulin (derived from chicory 
root) 
1,000 mg * 
 
Lactobacillus acidophilus 3.7+ billion 
CFUs 
* 
 
Bifidobacterium bifidum 1.4+ billion 
CFUs 
* 
 
Proprietary Blend of: 4.9+ billion 
CFUs 
* 
 
Lactobacillus bulgaricus   
 
Lactobacillus rhamnosus   
 
Lactobacillus brevis   
 
Streptococcus thermophilus   
 
Lactobacillus casei   
 
Lactobacillus salivarius   
 
Lactobacillus plantarum   
 
Bifidobacterium lactis 
Figure 6: Probiotic Group 5 (Green)
Figure 7: Color coding of probiotics     Figure 8: Commercial Probiotics utilized 
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 Pathogenic Strain Selection: 
E. faecalis was chosen for this study after extensive literature review which had revealed that this 
organism possesses multiple properties leading to its key role as an endodontic pathogen. Some 
of these features: (37, 38):
1. It is resistant to most of the intra-canal medicaments, particularly calcium hydroxide 
dressing due to its ability to regulate internal pH with an efficient proton pump.
2. E. faecalis can survive prolonged starvation. 
3. Controlled studies have shown that E. faecalis is the pathogen of significance in most 
cases of failing endodontic treatment.  
C. albicans was chosen as another pathogenic test organism due to: (1, 3) 
1. It’s biphasic nature which allows it to be the universal co-aggregate in biofilms.  
2. It is the most frequently isolated fungus from root filled teeth with apical periodontitis.
 Extraction of Probiotic Organisms From Commercial Products: 
Klaire® Labs, a division of Prothera Inc®, was contacted after purchasing and receipt of 
the probiotics that were intended for experimentation.  The lab forwarded an extraction method 
for re-growing and culturing the microorganisms. 
The following protocol was followed for the extraction/culturing method: 
1. An aseptic protocol was followed for every extraction method via spraying the 
operative fields with 99% ethyl alcohol, followed by Cavicide™ spray or wipes.  The operative 
fields were then left to dry.  For manipulation of probiotics and extraction processes, sterile 
gloves were utilized to decrease any cross-contamination.  All instruments such as sterile plastic 
pliers/loops were discarded after single use. 
2.1.1 Grams of the dried probiotic powder of groups 1 through 5 were weighed 
aseptically on a lab scale. The measured powder was aseptically placed into sterile 15 ml 
test tubes containing 10 ml of sterile MRS broth. 
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3. The tubes were then vortexed at room temperature on a vortex mixer (Fisher 
Scientific™ Digital mixer) for two minutes until the mixture was homogenous. 
4. The samples were then kept at room temperature for 30 minutes to assure rehydration 
of the freeze-dried powder. 
5. The samples were then returned to the vortex machine and vortexed for an additional 
two minutes.
6. Samples where incubated at 37° C in an incubator for 48 hours (an anaerobic chamber 
would have been preferred for growth of the microorganisms, but was unavailable). 
7. Samples were then placed in the lab refrigerator at 4° C for no longer than two weeks 
before being used for testing to avoid any mutation in the test species. New probiotic 
stock was made every two weeks. 
8. Samples that were to be utilized for testing were transferred via a sterile pipette from 
the stock solution into 9 ml of MRS broth in sterile tubes and were adjusted to a 
McFarland Standard of 1 for standardization (1 McFarland = 3 X 108 CFU/ml) . 
9. To insure growth of microorganisms, 0.5 ml of the 1 McFarland mixture of the 
probiotic groups was transferred via a micropipette and spread on a blood agar plate or Mueller 
Hinton plates with an L-spreader, followed by incubation for 24 hours, 48 hours and 1 week. 
This was followed by gram staining and growth observation (CFU observation). 
(A) (B)                             (C)                                  (D) 
Figure 9: (A)L-spreader, (B) Micro-Pipette, (C) Sterile pliers and Loops, (D) Vortex 
machine  
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(A)                                                                       (B) 
Figure 10: (A) Probiotics in TSB broth (posterior) and MRS broth(anterior), (B)Probiotics 
in TSB broth 
Figure 11: Cultered proibiotics on Muller Hinton plates
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(A)                                                                          (B) 
Figure 12: (A) C.albicans lawn on blood agar plate, (B) E.faecalis on blood agar 
plate  
Steps done prior to the utilization of the probiotic blends to determine eligibility and presence of 
microorganisms prior to testing: 
A. Gram staining was performed on each sample after plating and growth on blood agar plates.  
Gram staining process was as follows: 
1. A 1 µL sample was taken using a sterile plastic loop from the probiotic inoculated blood 
agar plate, and then smeared on to a wet microscope glass slide.  All groups were tested 
(G1-G5). 
2. The glass slide was heat fixed to dry the smear of cells.
3. Crystal violet staining reagent was applied for 1 minute.
4. The slide was washed in a gentle and indirect stream of tap water for 2 seconds.
5. Gram's iodine was applied for 1 minute.
6. The slide was washed in a gentle and indirect stream of tap water for 2 seconds.
7. Decolorizing agent was applied to the slide for 15 seconds until the slide was clear,  
followed by a gentle wash of the slide with tap water for 2 seconds.
8. Safranin was the applied for 30 seconds, followed by a final rinse of tap water for 2 
seconds.
9. The slide was the left to air dry.
10. The results of the staining procedure were viewed using a Brightfield microscope. 
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11. At the completion of the gram stain, it is noted that gram negative bacteria stain 
pink/red whereas gram positive bacteria stain blue/purple.
Figure 13: Gram Stain
Figure 14: Gram stained probiotic slides 
Figure 15: Bright field microscope
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B. Live/dead staining was performed by live/dead Baclight™ bacterial viability kits for 
evaluation of cell viability for all test organisms.
The following protocol was followed: Staining Bacteria in suspension with kit L13152
1. A 2X stock solution of the live/deadD BacLight staining reagent mixture was prepared 
by dissolving the contents of one component A pipet (containing yellow-orange solids) 
and one component B pipet (containing red solids) in a common 5 mL–volume of filter-
sterilized H2O.
2. A sample of the 2X stock solution was combined with an equal volume of the bacterial 
suspension. The final concentration of each dye will be 6 μM SYTO 9 stain and 30 μM 
propidium iodide.  
3. The resulting solution was mixed thoroughly and incubated at room temperature in the 
dark for 15 minutes. 
4. 5 μL of the stained bacterial suspension was trapped between a slide and an 18 mm 
square coverslip. 
5. Fluorescence was observed under a Zeiss ® Axiovert 40 CFL™ inverted microscope 
with X-Cite® 120q wide field fluorescence microscope excitation source. 
Figure 16: Live/dead stain slides prepared for fluorescent microscope 
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Figure 17: X-Cite® 120q wide field fluorescence microscope excitation source 
Figure 18: Zeiss ® Axiovert 40 CFL™ inverted microscope
Figure 19: C. albicans budding under fluorescent microcsopy 
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Figure 20:Clusters of probiotic group 5 under fluorescent microcsopy 
Figure 21: Cluster of probiotic group 4 under fluorescent microcsopy 
24 
 
Phase 1: Testing for Probiotic efficacy against E. faecalis and C. albicans;
Planktonic Stage Evaluation. 
A disc diffusion assay test was conducted. The purpose of the Kirby-Bauer disc diffusion 
susceptibility test is to determine the sensitivity or resistance of pathogenic aerobic and 
facultative anaerobic bacteria to various antimicrobial compounds.  In this study, probiotics 
where used to determine their antimicrobial effect against pathogenic organisms.  The 
pathogenic organisms were grown on blood agar in the presence of test probiotic group 
impregnated filter paper discs. Observation of the presence or absence of growth around the 
discs is an indirect measure of the ability of that probiotic group to inhibit growth or out compete 
the pathogenic organisms E. faecalis or C. albicans. 
Testing: An aseptic technique (sterile pipette carriers, alcohol and Cavicide wipes for surfaces, 
sterile cotton pliers, sterile loops and sterile L-spreaders) was utilized throughout the procedure 
to insure sterile environment, as well as prevention of cross contamination.  
1. The five probiotic groups were extracted according to manufacturer’s instructions and 
incubated for 48 hours. 
2. Probiotic samples were then placed in 9ml MRS broth (De Man, Rogosa and Sharpe 
broth) and vortexed to insure a homogenous mixture, then set to a 2 McFarland standard 
via laser spectrophotometry (average 6 x 108 CFU/ml). 
3. The pathogenic organisms E. faecalis and C. albicans were freshly stocked, placed in 9 
ml TSB (tryptic soy broth) and vortexed to insure homogenous mixture, then set to a 1 
McFarland standard via laser spectrophotometry (average 3 x 108 CFU/ml). 
4. 500 microliters of E. faecalis was plated on 100 mm diameter blood agar plates and 
spread with a sterile L-Loop.  The sample was incubated for 24 hours to allow growth of 
a bacterial lawn. 
5. 500 microliters of C. albicans was plated on 100 mm diameter blood agar plates and 
spread with a sterile L-Loop. The sample was incubated for 24 hours to allow growth of a 
bacterial lawn. 
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6. 20 microliters of probiotic G I through G V were placed on sterile blank paper discs and 
left for 15 seconds to allow the discs to saturate with the probiotic cocktails.  The discs 
were then transferred to the previously grown lawns of the pathogenic test organisms, E.
faecalis and C. albicans, according to a 5 group template as seen in figure (22). 
7. The blood agar plates were then incubated at 37 ° C and evaluated at 48 hours and 168 
hours (1 week), respectively. 
8. The test was conducted three times per group against the organisms, E. faecalis and C. 
albicans to allow proper statistical analysis. 
9. The control was conducted by growing E. faecalis and C. albicans lawns at a 1 
McFarland standard with empty sterile discs placed on the lawns.  
10. Results for ZOI’s were measured with a digital micrometer in mm increments at 48 hours 
and 168 hours (1 week).  
 
Figure 22: Five disc probiotic template on plate 
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Figure 23: Digital Micrometer 
            Figure 24: Light Spectrophotometer 
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Figure 25: Illustration of five disc probiotic template on plates
                  
                           
Figure 26: Five disc probiotic template on blood agar plate  
1 
5 
2 
3 
4 
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Figure 27: Six plates with five disc probiotic template on blood agar plates 
Figure 28: Control four disc template on Muller Hinton plate 
Phase 2: Biofilm stage testing; Intra-canal delivery vehicle for probiotics
In this phase of the study, we evaluated biofilm staging by mixing pathogenic organisms 
with probiotic cocktails from individual groups, followed by serial dilutions and colony forming 
unit counts per ml.  Only G I and G IV were evaluated for this part of the study, since they 
demonstrated the most significant zones of inhibition.  G V was excluded from the study due to 
patent pending status of the probiotic cocktail. 
Stage 1: Making of the Delivery Vehicle  
Poloxamer F127 (407) was prepared by adding dry powder to the appropriate type 
and amount of broth (MRS and TSB were both utilized).   Prebiotic mixtures (Inulin, 
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Oligofructose , beta-glucan, larch arabinogalactan, glycerin and trechalose)  were initially 
mixed and were considered to be included as part of the formulation, but due to time 
limitations of the study and to avoid having too many variables, it was decided to remove 
these prebiotics from the mixture as well as to prove the concept of probiotics 
outcompeting pathogenic organisms in the biofilm stage.  This suggests that further 
studies be conducted with prebiotics added to the mixture and possibly enhancing the 
probiotic effect.  
The poloxamer was dissolved in cold MRS broth at a concentration of 30% by a 
magnetic stirrer for 10 to 15 minutes until a homogenous mixture was obtained.  The poloxamer 
was then sterilized and placed in the refrigerator at 4° C until testing was conducted.  The MRS 
broth mixture was utilized for this study. 
Figure 29: 30 % Poloxamer 407 (Pluronic F-127) with MRS broth 
Figure 30: Magnetic Stirrer 
Control testing: 
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E. faecalis and C. albicans stocks were both prepared in TSB broth to a McFarland 
Standard of 1 via light spectrophotometry.  A total of 9 mls of poloxamer was placed in a test 
tube and 500 ml of pathogenic organisms were added and vortexed at 4 °C in a refrigerated 
environment to allow homogenous mixture of poloxamer and microorganisms.  Samples were 
then incubated for 48 hours in an incubator at 37° C. 
After 48 hours, serial dilutions of the pathogenic biofilm samples were prepared and 
plated on blood agar plates to evaluate colony forming units of the organisms.  Serial dilutions 
were made by adding 0.1 ml of poloxamer mix to 9.9 ml sterile saline, followed by serially 
diluting the mixture by 0.1ml into 9.9 ml sterile saline three times, reaching dilutions of 10-2,      
10-4,10-6   respectively.   Plating was conducted by adding 500 ml of dilutions onto blood agar 
plates, followed by incubation at 37° C for 72 hours.  CFU counts were evaluated. 
Figure 31: (A) and (B) Control E.f and C.a in poloxamer 407
(A) (B) 
Figure 32: Serial Dilutions of E.faecalis and C.albicans 
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Figure 33: CFU/mL C.albicans 10-4 dilution    
Figure 34: CFU/mL E.faecalis 10-4 dilution    
Testing for probiotic/pathogenic organism Poloxamer mixture: 
1. 9 ml of the poloxamer mixture was placed in a test tube along with 500 ml of E. faecalis
at a 1 McFarland standard.  Following that, 500 ml of test probiotic group 1 was added at 
1.5 to 2 McFarland standards.   
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2. 9ml of the poloxamer mixture was placed in a test tube and 500 ml of E. faecalis was 
added at a 1 McFarland standard. Following that, 500 ml of test probiotic group 4 was 
added at 1.5 to 2 McFarland standards. 
3. 9ml of the poloxamer mixture was placed in a test tube and 500 ml of C albicans at a 1 
McFarland standard was added.  Following that, 500 ml of test probiotic group 4 was 
added at 1.5 to 2 McFarland standards.  
4. 9ml of the poloxamer mixture was placed in a test tube and 500 ml of C. albicans at a 1 
McFarland standard was added.  Following that, 500 ml of test probiotic group 4 was 
added at 1.5 to 2 McFarland standards.  
5. After 48 hours serial dilutions of the pathogenic biofilm samples were prepared and 
plated on blood agar plates to evaluate colony forming units of the organisms. 
6. Serial dilutions were made by adding 0.1 ml of poloxamer mix to 9.9 ml sterile saline , 
followed by serially diluting the mixture by 0.1ml into 9.9 ml sterile saline three times, 
reaching dilutions of 10-2, 10-4 ,10-6   respectively. 
7. Plating was conducted by adding 500 ml of the dilutions onto blood agar plates followed 
by incubation at 37° C for 72 hours.  CFU (colony forming units) were evaluated for all 
test groups and compared to controls based upon the dilutions that were performed to 
reflect the actual number of probiotics and pathogenic organisms in each group. 
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Figure 35: Poloxomer with pathogenic organisms and test probiotics 4 and 1 mixed 
together   
Figure 36: Serial dilutions of poloxamer/probiotic/pathogenic organisms mixed 
together. 
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Figure 37: Serial dilutions of poloxamer/probiotic/pathogenic organisms mixed 
together on blood agar plates. 
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Chapter IV 
Results 
Phase 1: ZOI
Probiotics were screened for their antimicrobial/outcompeting activity against the 
selected microbes, E. faecalis and C. albicans.
The preliminary screening showed that G I, IV and V had antimicrobial activity against 
the specific pathogenic microbes tested.   Clear zones of inhibition were seen around G I, IV and 
V with valid statistical significance (P<0.0001).  Groups II and III showed variable results and 
therefore it could not be concluded that they are fully effective against the specific pathogenic 
organisms tested, and were subsequently eliminated from the biofilm stage testing.  One 
observation in this study was that G I, IV and V all contained the common organisms L.
acidophilus, L. casei , L. rhamnosus  and B .longum in their groups, suggesting that further 
studies should focus on these particular organisms.   Another observation was that prior to zones 
of inhibition being seen, a zone of growth was noted 24 hours after plating, which was then 
followed by the observation of zones of inhibition beginning at 48 hours.  G III (Sachromyces 
boulardii) demonstrated a continuous ring or zone of growth around the disc with a small zone of 
inhibition against either of the pathogenic organisms.  G IV and V showed the largest ZOI 
diameters. 
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Zones were recorded via a digital micrometer and are noted in the table below (Table1) 
1-Candida albicans Test: 
 Table (1). ZOI Candida albicans 48Hours.
Candida 48hrs Group 1 Group 2 Group 3 Group 4 Group 5 
    Test 1 5.75mm 1.32mm 2.6mm 9.21mm 9.42mm 
    Test 2 5.01mm 0.96mm 2.3mm 8.26mm 11.32mm 
    Test 3 5.95mm 1.2mm 3.01mm 8.52mm 10.70mm 
      
 
ZOI at 48hrs for group 1, 4 and 5 were statistically significant compared to groups 2 and 3 (P< 
0.0001) against C. albicans.
(A)                                                                 (B) 
Figure 38: (A) and (B) ZOI’s for Candida albicans 48-72hrs with five disc template on 
blood agar. 
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Figure 39 :Control Candida albicans on blood agar plate. 
Figure 40: C.albicans and E.faecalis ZOI’s (multiple plates).
Figure 41: ZOI’s for Candida albicans 1 week with five disc templates on blood agar. 
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Figure 42: Zone of growth 24hrs for Candida albicans on blood agar. 
 Table (2). ZOI Candida albicans 1 week.  
   Candida  
   1 week 
Group 1 Group 2 Group 3 Group 4 Group 5 
Test 1 7.05 mm 2.1mm 3.21mm 9.94mm 10.79mm 
Test 2 7.24mm 2.13mm 3.26mm 9.82mm 12.64mm 
Test 3 7.95mm 1.89mm 3.3mm 10.4mm 12.53mm 
      
 
ZOI at 1 week for group 1, 4 and 5 were statistically significant compared to groups 2 and 3 (P< 
0.0001) against C. albicans.
Statistical analysis was conducted by least squares means and one way ANOVA for comparing 
all groups. 
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(A)                                                               (B) 
Figure 43: (A) and (B) ZOI’s for Candida albicans one week with five disc template on 
blood agar. 
 Whole Model for Candida albicans:48hrs and 1 week
 Table ( 3 ) .Analysis of variance (ANOVA) for Zone of Inh by Group =CA 
Analysis of Variance
Source DF Sum of 
Squares
Mean Square F Ratio
Model 9 415.49452 46.1661 153.8561
Error 20 6.00120 0.3001 Prob > F
C. 
Total
29 421.49572 <.0001*
 
 Table (4). Effect Tests for Zone of Inh by Group =CA 
40 
 
Effect Tests
Source Nparm DF Sum of 
Squares
F Ratio Prob > 
F
time 1 1 11.68128 38.9298 <.0001*
Group 4 4 402.35629 335.2299 <.0001*
time*Group 4 4 1.45695 1.2139 0.3361
 
 Table (5).Least Squares Means Whole Model=CA
Level Least Sq 
Mean
Std Error Mean
Group 
1
6.491667 0.22362916 6.4917
Group 
2
1.600000 0.22362916 1.6000
Group 
3
2.946667 0.22362916 2.9467
Group 
4
9.358333 0.22362916 9.3583
Group 
5
11.233333 0.22362916 11.2333
time*Group
• Table (6) .Least Squares Means by Day=CA
Least Squares Means Table
Level Least Sq 
Mean
Std Error
2 days,Group 1 5.570000 0.31625939
2 days,Group 2 1.160000 0.31625939
2 days,Group 3 2.636667 0.31625939
2 days,Group 4 8.663333 0.31625939
2 days,Group 5 10.480000 0.31625939
7 days,Group 1 7.413333 0.31625939
7 days,Group 2 2.040000 0.31625939
7 days,Group 3 3.256667 0.31625939
7 days,Group 4 10.053333 0.31625939
7 days,Group 5 11.986667 0.31625939
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 Figure 44: LS Means Plot Candida albicans 
(A)                                                                                 (B) 
Figure 45: (A) and (B) LS Means bar Graph C .albicans
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2-E.faecalis test: 
 Table (7). ZOI Enterococci faecalis 48Hours. 
 
E.faecalis  
48 Hrs 
Group 1  Group 2 Group 3 Group 4 Group5 
Test 1 5.08mm 2.8mm 4.97mm 8.96mm 10.23mm 
Test 2 5.36mm 1.56mm 4.03mm 9.84mm 9.55mm 
Test 3 6.04mm 2.09mm 3.6mm 10.13mm 9.9mm 
      
      
 
 
 
 
ZOI at 48hrs for group 1, 4 and 5 were statistically significant compared to groups 2 and 3 (P< 
0.0001) against E. faecalis. 
(A)                                     (B)                                       (C) 
Figure 46: (A), (B) and (C) ZOI’s for Enterococci faecalis 48-72hrs with five disc templates 
on blood agar. 
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Figure 47: E.faecalis and C.albicans ZOI’s (multiple plates).
Figure 48: Zone of growth 24hrs for Enterococci faecalis on blood agar. 
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(A)                                                                 (B) 
Figure 49: (A) and (B) ZOI’s for Enterococci faecalis 48-72hrs with five disc template on 
blood agar.
 Table (8). ZOI Enterococci faecalis 1 week.
E.faecalis  
1 week 
Group 1 Group 2 Group 3 Group 4 Group 5 
Test 1 6.01mm 4.61mm 5.3mm 9.9mm 12.8mm 
Test 2 6.2mm 4.47mm 5.4mm 11.92mm 12.2mm 
Test 3 7.9mm 3.89mm 4.2mm 11.6mm 12.72mm 
      
 
 
ZOI at 1 week for group 1, 4 and 5 were statistically significant compared to groups 2 and 3 (P< 
0.0001) against E. faecalis.
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(A)                                                                                                  (B) 
                                        
(C)                                                                                   (D) 
Figure 50: (A), (B), (C) and (D) ZOI’s for Enterocci faecalis one week with five disc 
template on blood agar. 
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Statistical analysis was conducted by least squares means and one way ANOVA for comparing 
all groups. 
 Whole Model for Enterococci faecalis:48hrs and 1 week
 Table (9). Analysis of variance (ANOVA) for Zone of Inh by Group =EF
Analysis of Variance
Source DF Sum of Squares Mean Square F Ratio
Model 9 325.38508 36.1539 79.1870
Error 20 9.13127 0.4566 Prob > F
C. Total 29 334.51635 <.0001*
 
 Table (10). Effect Tests for Zone of Inh by Group =EF
 
Effect Tests 
Source Nparm DF Sum of 
Squares 
F Ratio Prob > F   
time 1 1 20.80001 45.5578 <.0001*
Group 4 4 301.08858 164.8668 <.0001*
time*Group 4 4 3.49649 1.9146 0.1473
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 Table(11) .Least Squares Means Whole Model=EF 
Least Squares Means Table
Level Least Sq 
Mean
Std Error Mean
Group 
1
6.098333 0.27585121 6.0983
Group 
2
3.236667 0.27585121 3.2367
Group 
3
4.583333 0.27585121 4.5833
Group 
4
10.391667 0.27585121 10.3917
Group 
5
11.233333 0.27585121 11.2333
 
Time*Group 
Table (12). Least Squares Means by Day=EF
Level Least Sq 
Mean
Std Error
2 days,Group 1 5.493333 0.39011252
2 days,Group 2 2.150000 0.39011252
2 days,Group 3 4.200000 0.39011252
2 days,Group 4 9.643333 0.39011252
2 days,Group 5 9.893333 0.39011252
7 days,Group 1 6.703333 0.39011252
7 days,Group 2 4.323333 0.39011252
7 days,Group 3 4.966667 0.39011252
7 days,Group 4 11.140000 0.39011252
7 days,Group 5 12.573333 0.39011252
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Figure (51): LS Means plot E. faecalis
(A)                                                               (B) 
Figure 52: (A) and (B) LS Means bar Graph E. faecalis 
Based on the statistical analysis, G I , IV and V were all effective in inhibiting and/or 
outcompeting endodontic pathogenic organisms E. faecalis and C. albicans showing a tangible 
ZOI (P<0.0001). 
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Phase 2: Biofilm staging and CFU counts 
Colony forming unit counts were conducted manually by dividing the blood agar plates 
into four quadrants and counting the colonies in each segment with a click counter and a pen. 
Controls of E. faecalis and C. albicans in the poloxamer mixture were plated after serial 
dilutions of 10-2,    10-4, and 10-6. Dilutions of (10-2) both pathogenic organisms showed colonies 
which were too numerous to count (10-4).   Dilutions of (10-4) showed 7.5 x 105 (75) colonies for 
C. albicans, and 1.75 x 106 (175) colonies for E. faecalis.  (10-6) dilutions of (10-6) showed 3 
colonies for C. albicans and 7 colonies for E. faecalis. 
After CFU count was conducted for the controls, test probiotic groups I and IV were 
mixed with the pathogenic organisms in the poloxamer mixture, plated and counted. 
Colonies of the probiotics were less, compared to colonies of the controls.  Due to financial 
limitations of the study, PCR (DNA or RNA sequencing) testing was not conducted, but random 
sampling by a sterile loop was taken from the colonies on the blood agar test plate, followed by 
gram staining and observation under a light microscope for evaluation of type of organisms 
present.  None of the probiotic groups had yeast or cocci; therefore any observations of yeast or 
cocci during the random sampling would have indicated incomplete elimination of either of the 
pathogenic organisms. 
Multiple random samples were taken from the plates.  No cocci were found in the random 
samples, indicating that E. faecalis was completely eliminated in the biofilm stage when mixed 
with either groups I or IV.
Yeast (C. albicans) colonies were found in the samples, but were limited in colony 
numbers and were easily distinguished from probiotics due to the size of the yeast colony. 
Results for the probiotic/pathogenic organism poloxamer mixture were as follows: 
Yeast (C. albicans) colonies were found in the samples but were limited in colony numbers and 
were easily distinguished from probiotics due to the size of the yeast colony.  Results for the 
probiotic /pathogenic organism poloxamer mixture were as follows: 
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Figure 53: Poloxomer with pathogenic organisms and test probiotics 4 and 1 mixed 
together   
 
  
Figure 54: CFU/mL Group I and C.albicans 10-4 dilution -72hrs
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Figure 55: CFU/mL Group IV and C.albicans 10-4 dilution -72hrs
 
  
Figure 56: CFU/mL C.albicans 10-4 dilution (Control) -72hrs 
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Figure 57: CFU/mL Group IV and E.faecalis 10-4 dilution -72hrs
 
 
 
Figure 58: CFU/mL Group 4 and E.faecalis 10-4 dilution -72hrs
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Figure 59: CFU/mL E.faecalis 10-4 dilution (Control) -72hrs
 
 
Poloxamer results (Biofilm stage testing): 
 
 Table (13). CFU/mL Candida albicans -72hrs 
 
Test organism         Group 1 test 
( Candida and Group 1) 
         Group 4 test 
(Candida and Group 4) 
Control (Candida alone) 
Candida colonies           4.0 x103    
  ( 2 log difference) 
         1.5x 104   
 (1 log difference) 
             7.5x105  
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Figure 60: CFU/ml For Candida albicans (control), Group 1 and Group 4 mixed with 
Poloxamer-72hrs-Bar Graph 
 
 
 Table (14). CFU/mL Enterococci faecalis -72hrs 
 
 
Test Organism Group 1 test 
(E. f and Group 1) 
Group 4 test 
(E. f and Group 4) 
Control(E .faecalis 
alone) 
E.Faecalis colonies 10-1 10-1 1.75 x106 
 
Figure 61: CFU/ml For Enterococcus faecalis (control), Group I and Group IV mixed with 
Poloxamer-Bar Graph 
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Figure 62: Poloxamer gel with group 1 in a syringe for intra-canal delivery. 
Discussion 
The main goal of endodontic therapy is to obtain an effective cleaning and 
decontamination of the root canal system.  Traditional endodontic techniques employ mechanical 
instrumentation, chemical irrigation and irrigant activation devices such as sonics, ultrasonics 
and lasers, to assist in the attempt to clean, shape and decontaminate all areas of the root canal.  
Even with all the advancements in technology, endodontic therapy still falls short of successfully 
removing all of the infective microorganisms and debris.  This is due to the complexity of the 
root canal anatomy and the inability of common irrigants to penetrate into lateral canals and 
apical ramifications.  Therefore, it seems appropriate to search for new materials, techniques and 
technologies that can improve the cleaning and decontamination of these anatomical areas.   
In this study, an innovative approach which might aid in increasing success of endodontic 
therapy was investigated.  This innovative approach involves Bacteriotherapy by allowing 
probiotic organisms to eliminate pathogenic organisms, either by outcompeting/immune-
modulation or by secreting antimicrobial substances such as peroxides.  The rationale behind this 
innovative Bacteriotherapy model evolved after extensive research was done to uncover any 
missing links in endodontic treatment.   Due to the fact that we cannot sterilize a root canal 
system because of its complex anatomical structure, it was hypothesized that microorganisms 
existing after treatment and which are considered healthy co-existents at a level where the human 
body is able to resist damage or destruction to its tissues, might decrease the incidence of 
endodontic failure. To date, total elimination of bacteria from the root canal system has been 
the focus of all endodontic procedures, but the fact that some organisms are beneficial 
throughout the human body has been ignored.  That same condition might also exist within root 
canals of human teeth.  In addition to eliminating and out competing the pathogens that 
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originally entered from the carious process, probiotic organisms could well not only eliminate 
disease causing bacteria, but might also prevent their re-establishment after treatment has been 
completed.  It must be understood that the first life forms on earth were bacteria, appearing over 
4 billion years ago, and we continue to live in the age of bacteria dominance. All subsequent 
forms of life evolved to their present states, interacting and integrating with them.  Human 
beings appear to be free of bacteria until they pass through the heavily colonized birth canal, and 
arrive in the microbial world in which we reside.  Our exposed organs and digestive tract become 
niches for adapted microbes (probiotics).  These spaces reflect in part, the exterior environment 
of our bodies.  The contents of these organs are kept separated from the ‘‘interior’’ of the body 
by barriers that effectively cordon off the luminal microbes.   Humans have a developmental 
process for the expression of antimicrobial peptides which modulate the microbial ecosystem 
that begins to form at birth.  The process of colonization is dynamic, and creates the structured 
populations reached in the climax community. (28) This aggregate of organisms that resides are 
found in various areas such as the oral cavity, saliva, conjuctival fluid, skin, gastrointestinal tract, 
as well as numerous other areas of the body is defined as “The Human Microbiome”. (27, 28) 
One of the most studied organs which contain microbial communities is the human 
gastrointestinal tract which contains a very complex and dynamic microbial community, specific 
for each person depending upon environmental and genetic factors.  Each individual holds 
approximately 1.5 kg of bacteria within in their gastrointestinal tract. . (12, 13, 14, 17, 18, 19, 27, 28) 
The gut microbiota plays an important role in human health, not only due to its 
participation in the digestion process, but also for its critical function in the development of the 
gut and the immune system, along with regulation of absorption and storage of lipids.  Recent 
studies have suggested that specific aberrations in gut microbiota composition are associated 
with different diseases.  The rationale for modulating the gut microbiota by means of probiotics 
is derived from the importance of gut microbiota on host health. (27) 
It was suggested in this study that this very same concept be applied to endodontic 
therapy owing to the fact that the oral cavity is part of the “Oral Human Microbiome”, which in 
turn is part the “Human Microbiome”. (27, 28)
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This study involved two phases: phase one (discovery phase) and phase two (application 
phase).  Phase one was a Kirby-Bauer disc diffusion susceptibility test, utilized to determine the 
sensitivity or resistance of the pathogenic bacteria (E .faecalis or C. albicans) to various 
probiotic challenges. The pathogenic organisms were grown on blood agar in the presence of 
test probiotic groups impregnated filter paper discs. The absence of growth around the discs was 
an indirect measure of the ability of the test probiotic groups to inhibit growth/out compete the 
pathogenic organism’s E. faecalis or C .albicans.
The results of phase one suggested that  organisms such as Lactobacillus rhamnosus, 
Bifidobacterium bifidum, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus 
plantarum, Lactobacillus salivarius, Bifidobacterium longum, Streptococcus thermophilus, 
Lactobacillus bulgaricus, Lactobacillus paracasei, Bifidobacterium lactis and Bifidobacterium 
breve possess antimicrobial activity against Enterococcus faecalis and Candida albicans.  An
observation from this study is that groups 1, 4 and 5 all contained common probiotic organisms 
including L.acidophillus,L.rhamnosus,L.casei and B.Longum, suggesting future focus involve on 
these organisms for future studies.
Phase two was considered the application portion of the study, suggesting a novel 
delivery vehicle for probiotics into the root canal system by utilizing 30% poloxamer 407 (also 
known as pluronic F-127) mixed with MRS or TSB broth containing the probiotics.  Poloxamer 
has been utilized in biofilm stage testing of microorganisms.  Although this secondary purpose 
was not the main focus of this study, it investigated poloxamer as a delivery mechanism. 
Poloxamers are non-ionic polyethylene oxide (PEO) and polypropylene oxide (PPO) 
copolymers. They are biocompatible and are used in pharmaceutical formulations such as 
surfactants, emulsifying agents, solubilizing agents, dispersing agents, and in vivo absorbance 
enhancer 1; therefore they are considered as “functional excipients” because they are essential 
components, and play an important role in the formulation (42, 43, and 44) of multiple therapeutic 
agents.  
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Two polymers from this class, poloxamer 188 and poloxamer 407, show inverse 
thermosensitivity.  They are soluble in aqueous solutions at low temperatures (mainly 4°C), but 
will gel at higher temperatures (42, 44). These properties make them an ideal delivery vehicle for 
use as an intra-canal medicament between inter-appointment visits. 
Other advantages of poloxamer 407, which make it ideal for use in the root canal system 
is that it has already been employed in topical dosage forms of other surface applied 
formulations.  Poloxamer 407 has been used in vehicles for fluorinated dentifrices, eye 
applications and contraceptive gels.  A poloxamer based dental gel product has been used for 
treating patients with sensitive gums and teeth.  Other properties relevant to this study are that a 
poloxamer based gel has showed many favorable characteristics for use as a burn dressing by 
providing a non-toxic detergent covering to the wound. Other studies suggest that the gel itself 
may accelerate wound healing, making P 407 a suitable vehicle for gels intended to be applied 
for ulcers and traumatic lesions. It would be an ideal solution for apical periodontitis which is the 
main cause for endodontic failure (42, 43, 44).
The CFU/ml count results for this study revealed a complete elimination of E. faecalis
colony counts for probiotic groups 1 and 4 when mixed in equal amounts with E. faecalis in the 
30 % poloxamer/MRS broth formula when compared with controls, and a significant inhibition 
in CFU/ml counts for C. albicans in probiotic groups 1 and 4 when mixed in equal amounts with 
C. albicans in the 30 % poloxamer/MRS broth formula when compared with controls. 
The suggested protocol for the use of a poloxamer probiotic based inter-appointment 
medicament would be to replace the current use of calcium hydroxide. Calcium hydroxide 
possesses favorable antimicrobial properties, yet it still cannot eliminate all pathogenic 
organisms such as E. faecalis. The protocol for the probiotic medicament would be, instead of a 
microbial “elimination therapy” by the use of antimicrobial agents, substituted by a microbial 
“replacement therapy”.  Instead of attempting to eliminate pathogenic organisms by 
antimicrobial agents, probiotics would eliminate the endodontic pathogenic flora, allowing a 
more favorable/biocompatible environment after standard root canal therapy procedures were 
followed.  This suggested new protocol for therapy would include cleaning, shaping, irrigation 
and activation of irrigants to decrease the microbial load and remove organic tissue, followed by 
introducing the poloxamer based probiotic mixture for a period of one week.   This would allow 
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a more favorable bacterial community to exist by outcompeting or eliminating pathogenic 
organisms.  This would be followed by a second visit of disinfection and obturation to eliminate 
as many organisms as possible to avoid mutation.  If any organisms were to exist after that 
process, the probiotic “healthy flora” would exist in the root canal system, possibly showing a 
more favorable endodontic outcome.  
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Chapter V 
Conclusion 
The null hypothesis for this study was rejected, since groups I, IV and V showed 
statistically significant results (P< 0.05) for ZOI for evaluating planktonic stages, and a reduction 
in CFU/ml counts for biofilm stage testing against E. faecalis and C. albicans.  Within the 
limitations of this study, it was concluded in phase one that L. acidophilus, L. casei , L. 
rhamnosus  and B. longum were all strains found in common in the probiotic cocktails selected 
against the endodontic pathogenic organisms E. faecalis and C. albicans in planktonic stages,
exhibiting antimicrobial activity which was reflected by the zones of inhibition (ZOI) seen.  In 
phase two it was concluded that probiotic groups I and IV demonstrated a decrease in CFU/ml 
count of the pathogenic organisms E. faecalis and C. albicans in the biofilm stage when mixed 
together with the probiotics.  Another conclusion is that poloxamer 407 may be used as a 
delivery vehicle for probiotics in the root canal system as an inter-appointment medicament. This 
is due to its unique reverse gel physical properties as well as its biocompatibility.  This pilot 
study demonstrated that probiotics show a potential in root canal therapy, but further in vitro and 
in vivo studies are needed to determine the full potential of “Bacteriotherapy” and its application 
in endodontics.  This model, if successful, may well be introduced and adapted in wound care 
management, since apical periodontitis can be considered a chronically existing wound, similar 
in nature to soft tissue wounds that are recalcitrant to standard antimicrobial therapies.    
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